CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program - CytoDyn Inc.

3/30/2022 12:00:00 AM3 years 1 month ago

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

Live webcast to be held March 31 discussing announcement VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology… [+6090 chars]

full article...

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program - CytoDyn Inc.

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.&nbsp; CCR5 appears to play&#8230;

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…